文献速递血栓与止血

生长分化因子-15与静脉血栓栓塞症患者出血风险

Growth differentiation factor-15 and bleeding risk in patients with venous thromboembolism.
PubMed 文献 · J Thromb Haemost · 2026-06-26

本研究基于BACH-VTE队列,纳入383例急性症状性肺栓塞或深静脉血栓患者,评估生长分化因子-15(GDF-15)对临床相关出血(CRB)的预测价值。结果显示基线GDF-15与CRB无显著关联,且未能改善VTE-PREDICT出血风险评分的预测性能。

要点

  • 在急性VTE抗凝患者中,基线GDF-15水平与临床相关出血风险无独立关联。
  • 将GDF-15加入VTE-PREDICT评分未显著提升出血预测能力。
  • ABC-bleeding评分在本队列中对CRB的区分度仅为中等。

核心结论

  • 在急性VTE抗凝患者中,GDF-15与临床相关出血无关,且不能改善出血预测。

研究设计与样本

  • BACH-VTE队列研究的一部分,纳入383例急性症状性肺栓塞或深静脉血栓患者,随访2年。
  • 排除活动性癌症及妊娠/围产期患者,基线及3个月时检测GDF-15。

主要发现

  • 中位随访178天,49例发生首次CRB,1年累积发生率为11.9%(95%CI 8.7-15.7)。
  • 基线GDF-15中位水平为968(IQR 645-1554)pg/mL,3个月时为836(597-1292)pg/mL。
  • 基线GDF-15与CRB在单变量(亚分布风险比1.05,95%CI 0.76-1.46)和多变量模型(0.96,95%CI 0.70-1.30,每倍增,调整出血史、年龄和性别)中均无关联。
  • GDF-15未显著改善VTE-PREDICT评分的预测性能;ABC-bleeding评分在本队列中区分度中等。

临床怎么用

  • 对于急性VTE抗凝患者,不推荐使用GDF-15来预测临床相关出血风险。
  • VTE-PREDICT评分加入GDF-15并未提升预测能力,临床应继续使用现有验证工具。

局限性

  • 本研究为观察性队列研究,样本量有限,结果需进一步验证。
  • GDF-15仅在基线和3个月时检测,未评估动态变化。
  • 排除活动性癌症和妊娠患者,结论可能不适用于这些人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Growth differentiation factor-15 (GDF-15) has been proposed as a bleeding biomarker. OBJECTIVES: To evaluate the predictive value of GDF-15 for clinically relevant bleeding (CRB, major bleeding and clinically relevant non-major bleeding) during anticoagulation for venous thromboembolism (VTE). METHODS: This study was part of BACH-VTE, a cohort study including patients with acute, symptomatic pulmonary embolism or deep vein thrombosis with 2 years of follow-up. Patients with active cancer and pregnant/peripartum were excluded. GDF-15 was measured at baseline and 3 months. CRB cumulative incidences and regression models were adjusted for competing risks (death/anticoagulation stop). The performance of the VTE-PREDICT bleeding risk score with and without GDF-15 and the ABC-bleeding risk score, which includes GDF-15, was analyzed by assessing discrimination, calibration, and overall performance. RESULTS: Among 383 patients (39.2% female, median age 55 years, 48.0% with pulmonary embolism), 49 first CRB occurred (median follow-up: 178 days), corresponding to a 1-year cumulative incidence of 11.9% (95% confidence interval [95% CI]: 8.7-15.7). Median GDF-15 levels were 968 (interquartile range, 645-1554) pg/mL at baseline and 836 (597-1292) pg/mL at 3 months. Baseline GDF-15 was not associated with CRB in the univariable or multivariable model (subdistribution hazard ratio 1.05 [95% CI: 0.76-1.46] and 0.96 [95% CI: 0.70-1.30] per doubling, adjusted for bleeding history, age, and sex). Accordingly, GDF-15 did not meaningfully improve the predictive performance of VTE-PREDICT. ABC-bleeding showed modest discrimination for CRB in this cohort. CONCLUSION: In patients receiving anticoagulation for acute VTE, GDF-15 was not associated with CRB and did not improve bleeding prediction.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Hoberstorfer T, Nopp S, Steiner D, et al. Growth differentiation factor-15 and bleeding risk in patients with venous thromboembolism. J Thromb Haemost. 2026. PMID: 42362032. doi:10.1016/j.jtha.2026.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。